<DOC>
	<DOCNO>NCT00023634</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may make body build immune response kill cancer cell . PURPOSE : This phase I trial study two different vaccine treat patient gastric , prostate , ovarian cancer .</brief_summary>
	<brief_title>S0114 Vaccine Therapy Treating Patients With Gastric , Prostate , Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity EGFRvIII peptide vaccine sargramostim ( GM-CSF ) keyhole limpet hemocyanin ( KLH ) adjuvant patient EGFRvIII-expressing cancer . - Determine preexist antibody T-cell response EGFRvIII patient . - Determine antibody T-cell responses EGFRvIII peptide immunization vaccine GM-CSF KLH adjuvant . OUTLINE : Patients assign one two treatment arm . - Arm I : Patients receive vaccine contain EGFRvIII peptide admix sargramostim ( GM-CSF ) intradermally monthly . - Arm II : Patients receive vaccine contain EGFRvIII peptide admix keyhole limpet hemocyanin subcutaneously monthly . Treatment arm continue 6 month absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 24 patient ( 12 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one following : Stage IIIV gastric cancer Stage IICIV ovarian cancer first complete remission CA 125 normal stable* Grade III anaplastic astrocytoma Stage IV ( M1 ) prostate adenocarcinoma No small cell variation No biochemical progression definitive surgery , define follow : Prostatespecific antigen 0.4 ng/mL remain elevated 2 additional measurement least 2 week apart prostatectomy Three consecutive rise PSA , least 1 month apart definitive radiotherapy Must receive androgen blockade PSA le 5 ng/mL stable* Documented EGFRvIII expression primary tumor Must receive prior surgery chemoradiotherapy disease ( except prostate cancer patient ) NOTE : *Stable defined increase 2 measurement least 28 day apart last measurement within past 28 day PATIENT CHARACTERISTICS : Age : 80 Performance status : Zubrod 0 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : SGOT great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN No hepatitis Renal : Not specify Other : No malignancy past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission No contraindication receive sargramostim ( GMCSF ) KLHbased vaccine product No autoimmune disease HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 1 month since prior cytotoxic chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 1 month since prior treatment dose corticosteroid No concurrent corticosteroid Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : See Disease Characteristics Other : Recovered prior therapy No concurrent enrollment phase I study No concurrent immune modulators</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
</DOC>